John M Kirkwood

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
    John M Kirkwood
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 1862, USA
    Cancer Treat Rev 39:27-43. 2013
  2. ncbi New therapies in the treatment of melanoma
    Diwakar Davar
    University of Pittsburgh, Medicine, 200 Lothrop Street, Pittsburgh 15213, PA, USA
    Expert Opin Investig Drugs 21:1643-59. 2012
  3. ncbi Immunotherapy of cancer in 2012
    John M Kirkwood
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    CA Cancer J Clin 62:309-35. 2012
  4. ncbi The role of BRAF V600 mutation in melanoma
    Paolo A Ascierto
    Department of Melanoma, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy
    J Transl Med 10:85. 2012
  5. ncbi Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  6. ncbi Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
    John M Kirkwood
    Departments of Medicine and Dermatology, University of Pittsburgh, PA 15213, USA
    Clin Cancer Res 18:555-67. 2012
  7. ncbi Multiplex serum biomarker assessments: technical and biostatistical issues
    Lisa H Butterfield
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Transl Med 9:173. 2011
  8. ncbi Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Transl Med 9:78. 2011
  9. ncbi Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
  10. ncbi A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008

Collaborators

Detail Information

Publications116 found, 100 shown here

  1. ncbi Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
    John M Kirkwood
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 1862, USA
    Cancer Treat Rev 39:27-43. 2013
    ....
  2. ncbi New therapies in the treatment of melanoma
    Diwakar Davar
    University of Pittsburgh, Medicine, 200 Lothrop Street, Pittsburgh 15213, PA, USA
    Expert Opin Investig Drugs 21:1643-59. 2012
    ..The understanding of these two facets of the disease will provide a more rational basis for the delivery of individualized therapy for the disease both in its advanced setting, and in the adjuvant arena, in the future...
  3. ncbi Immunotherapy of cancer in 2012
    John M Kirkwood
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    CA Cancer J Clin 62:309-35. 2012
    ....
  4. ncbi The role of BRAF V600 mutation in melanoma
    Paolo A Ascierto
    Department of Melanoma, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy
    J Transl Med 10:85. 2012
    ....
  5. ncbi Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  6. ncbi Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
    John M Kirkwood
    Departments of Medicine and Dermatology, University of Pittsburgh, PA 15213, USA
    Clin Cancer Res 18:555-67. 2012
    ....
  7. ncbi Multiplex serum biomarker assessments: technical and biostatistical issues
    Lisa H Butterfield
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Transl Med 9:173. 2011
    ..Many of these studies seek biomarkers among circulating proteins accessed in blood. Many levels of standardization in materials and procedures have been identified which can impact the resulting data...
  8. ncbi Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients
    Luca Sigalotti
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy
    J Transl Med 9:78. 2011
    ..Genome-wide alterations in DNA methylation are a common event in cancer. This study aimed to define the prognostic value of genomic DNA methylation levels in stage III CM patients...
  9. ncbi Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
    ..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
  10. ncbi A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  11. ncbi Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Antoni Ribas
    University of California, 11 934 Factor Building, UCLA Medical Center, Los Angeles, CA 90095 1782, USA
    J Transl Med 7:68. 2009
    ..18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood...
  12. ncbi Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  13. ncbi Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapy and Melanoma Cooperative Group, National Tumor Institute, Naples, Italy
    J Transl Med 8:76. 2010
    ....
  14. ncbi Adjuvant therapy of melanoma with interferon: lessons of the past decade
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapy, Melanoma Cooperative Group, National Tumor Institute, Naples, Italy
    J Transl Med 6:62. 2008
    ..Future efforts may well build toward patient-oriented therapy based upon the knowledge of the unique molecular features of this disease and the immune system of each melanoma patient...
  15. ncbi Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
    ..Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity...
  16. ncbi Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients
    Diana L Simons
    Dept of Medicine, Stanford University, Stanford, CA, USA
    J Transl Med 9:52. 2011
    ..This exploratory study evaluated IFN signaling in PBL of melanoma patients to assess whether the restoration of PBL IFN signaling may predict a beneficial effect for HDI in melanoma patients...
  17. ncbi Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Nat Clin Pract Oncol 5:2-3. 2008
  18. ncbi Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 2584, USA
    Clin Cancer Res 15:1443-51. 2009
    ....
  19. ncbi Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations
    John M Kirkwood
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 2584, USA
    Clin Cancer Res 12:2331s-2336s. 2006
    ..These new insights will allow us to develop more efficient approaches to adjuvant therapy of melanoma, focusing on autoimmunity and antitumor immunity with new immunomodulators, such as anti-CTLA4 antibodies and vaccination...
  20. ncbi Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
    ..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States...
  21. ncbi Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
    John M Kirkwood
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 16:1042-8. 2010
    ..This phase II study assessed the antitumor activity of tremelimumab, a fully human, anti-CTL-associated antigen 4 monoclonal antibody, in patients with melanoma...
  22. ncbi Melanoma in pediatric, adolescent, and young adult patients
    John M Kirkwood
    Department of Medicine, University of Pittsburgh School of Medicine, and Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Semin Oncol 36:419-31. 2009
    ....
  23. ncbi One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma
    Maja Mandic
    Department of Medicine and The Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunol 174:1751-9. 2005
    ..They also support the relevance of cancer vaccine trials with peptides NY-ESO-1 87-111 in the large number of cancer patients with NY-ESO-1-expressing tumors...
  24. ncbi Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients
    Pavol Kudela
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 179:7932-40. 2007
    ..Our findings have significant implications for the optimization of TCR gene transfer immunotherapies widely applicable to cancer patients...
  25. ncbi PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients
    Julien Fourcade
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 182:5240-9. 2009
    ..They further support the use of PD-1/PD-L1 pathway blockade in cancer patients to partially restore NY-ESO-1-specific CD8(+) T cell numbers and functions, increasing the likelihood of tumor regression...
  26. ncbi MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma
    Tomohide Tatsumi
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Cancer Res 9:947-54. 2003
    ..These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma...
  27. ncbi Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire
    Julien Fourcade
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 2582, USA
    J Immunol 184:6709-18. 2010
    ..They also suggest that TA-specific Treg expansion may be better impaired by therapies aimed at depleting CD4+CD25high Tregs and preventing the peripheral conversion of CD4+CD25- T cells...
  28. ncbi Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients
    Julien Fourcade
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 2582, USA
    J Immunother 31:781-91. 2008
    ..They also suggest that the presence of tumor-induced NY-ESO-1-specific T cells of well-defined clonotypes is critical for the expansion of tumor-reactive NY-ESO-1-specific CD8+ T cells after peptide-based vaccine strategies...
  29. ncbi Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1
    Pavol Kudela
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 186:312-22. 2011
    ..Therefore, they provide a strong rationale for the inclusion of LAGE-1 peptides or protein in vaccine trials for patients with NY-ESO-1(+)/LAGE-1(+) tumors...
  30. ncbi Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma
    Stergios J Moschos
    University of Pittsburgh Cancer Institute, PA, USA
    J Immunother 33:316-25. 2010
    ..No apparent antiangiogenic or immunomodulatory effects of etaracizumab were noted...
  31. ncbi Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents
    Stergios J Moschos
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, PA 15213 2584, USA
    Melanoma Res 17:193-200. 2007
    ..Better laboratory correlates of antiangiogenic response are needed, and the predictive value of circulating endothelial cells warrants further evaluation...
  32. ncbi Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b
    Wenjun Wang
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute Pittsburgh, PA, USA
    Clin Cancer Res 13:1523-31. 2007
    ..The goal of this study was to understand the effects of high-dose IFNalpha2b (HDI) in relation to the balance of pSTAT1 and pSTAT3...
  33. ncbi Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells
    Jeffrey L Wong
    Department of Surgery, University of Pittsburgh, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 1863, USA
    J Immunother 34:270-8. 2011
    ..These results indicate that the helper function of NK cells can be used in clinical settings to improve the effectiveness of DC-based cancer vaccines...
  34. ncbi Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma
    Wenjun Wang
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Avenue, Pittsburgh, PA 15213 2584, USA
    Cancer Immunol Immunother 57:1315-21. 2008
    ..We have therefore evaluated STAT3 and MEK/ERK MAP kinases in patients with regional lymph node metastasis (stage IIIB) of melanoma in the context of a prospective neoadjuvant trial of HDI (UPCI 00-008)...
  35. ncbi Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
    J Immunother 35:702-10. 2012
    ..T-reg findings suggest that IFN/treme induced clinically significant antitumor responses by inhibiting CTLA4 suppressive effects on T effectors, and less so by affecting T-reg...
  36. ncbi A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
    John M Kirkwood
    University of Pittsburgh Medical Center, Department of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 10:1670-7. 2004
    ..The objectives of this study were to update the analyses of each individual trial and to analyze prognostic factors and treatment effects based on pooled data...
  37. ncbi Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro
    Amy Wesa
    Department of Dermatology, University of Pittsburgh School of Medicine, PA 1513, USA
    J Immunother 30:75-82. 2007
    ..These results suggest that preexisting CD4+ T cell immunity to cancer is not relegated to Type-1 insufficiency and may be corrected via the application of DC1-based vaccination protocols...
  38. ncbi Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers
    Bratislav Janjic
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 177:2717-27. 2006
    ..Because of its immunodominance, peptide TRAG-3(34-48) is of particular interest for the monitoring of spontaneous immune responses in patients with TRAG-3-expressing tumors and for the development of cancer vaccines...
  39. ncbi The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells
    Maja Mandic
    Department of Medicine and Melanoma Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Res 63:6506-15. 2003
    ....
  40. ncbi Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Ave, Fifth Fl, Pittsburgh, PA 15232, USA
    J Clin Oncol 30:322-8. 2012
    ..We tested the hypothesis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly synergistic mechanisms would overcome tumor immune tolerance and lead to significant and durable clinical responses...
  41. ncbi STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy
    Wenjun Wang
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 2584, USA
    J Invest Dermatol 128:1997-2002. 2008
    ..pSTAT3 is a potential biomarker of melanocytic transformation and progression and is modulated by IFNalpha dose-dependently. STAT3 is a potential target for chemoprevention of melanoma...
  42. ncbi A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 113:1632-40. 2008
    ..Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy...
  43. ncbi IL-18-induced CD83+CCR7+ NK helper cells
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, PA, USA
    J Exp Med 202:941-53. 2005
    ..The current data demonstrate independent regulation of the "helper" versus "effector" pathways of NK cell differentiation and novel mechanisms of immunoregulation by IL-18 and PGE2...
  44. ncbi Focus on FOCIS: interleukin 2 treatment associated autoimmunity
    Stergios J Moschos
    University of Pittsburgh Federation of Clinical Immunologic Societies Center of Excellence, Pittsburgh, Pennsylvania 15213 1683, USA
    Clin Immunol 127:123-9. 2008
    ..We present studies investigating the mechanisms for the therapeutic benefit of HDIL2 in melanoma...
  45. ncbi A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma
    John M Kirkwood
    Melanoma and Skin Cancer Program, University of Pittsburgh Medical Center, Pennsylvania, USA
    Cancer 117:4732-9. 2011
    ....
  46. ncbi Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials
    Uma N M Rao
    Department of Pathology, University of Pittsburgh Medical Center, Presbyterian Shadyside Hospitals, PA, USA
    Am J Clin Pathol 133:646-53. 2010
    ..This study confirmed the importance of tumor ulceration and the number of positive lymph nodes on outcome...
  47. ncbi Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)
    Carsten Schaefer
    Department of Pathology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Int J Cancer 131:874-84. 2012
    ..Phenotypic analyses of CD8(+) tet(+) T cells did not correlate with clinical responses to the vaccine, indicating that functional assessments of peptide-specific T cells are preferable for monitoring of anti-tumor vaccines...
  48. ncbi CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1
    Julien Fourcade
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer Res 72:887-96. 2012
    ..Collectively, our findings indicate that targeting BTLA along with the PD-1 and Tim-3 pathways is critical to reverse an important mechanism of immune escape in patients with advanced melanoma...
  49. ncbi Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17
    Wenjun Wang
    Department of Medicine, Division of Hematology Oncology, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213 2584, USA
    Clin Cancer Res 14:8314-20. 2008
    ..The effects of IFNalpha on STAT signaling in relation to tumor tissue Treg and Th17 have not been documented in humans beyond the observations that IFNalpha2b down-regulates STAT3...
  50. ncbi Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation
    Anna Wankowicz-Kalinska
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Melanoma Res 16:165-74. 2006
    ....
  51. ncbi Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Clin Oncol 25:3802-7. 2007
    ..We conducted a phase II trial of high-dose bolus (HDB) interleukin-2 (IL-2) in patients with metastatic melanoma who had experienced progression after biochemotherapy (BCT)...
  52. ncbi Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  53. ncbi Adjuvant high-dose interferon-alpha therapy for high-risk melanoma
    John M Kirkwood
    Division of Medical Oncology, University of Pittsburgh, 200 Lothrop Street, 15123 Pittsburg, Pennsylvania
    Forum (Genova) 13:127-40; quiz 187-8. 2003
    ..We also present selected ongoing trials testing potential future therapies that may prove effective for patients with high-risk resected melanoma...
  54. ncbi Importance of glycolysis and oxidative phosphorylation in advanced melanoma
    Jonhan Ho
    Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Mol Cancer 11:76. 2012
    ....
  55. ncbi Progression of cutaneous melanoma: implications for treatment
    Stanley P L Leong
    Center for Melanoma Research and Treatment and Department of Surgery, California Pacific Medical Center, San Francisco, CA, USA
    Clin Exp Metastasis 29:775-96. 2012
    ..With recent developments in molecular biology and genomics, novel molecular targeted therapy is being developed through clinical trials...
  56. ncbi Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    J Immunother 35:359-66. 2012
    ....
  57. ncbi Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study
    Sanjiv S Agarwala
    Melanoma Center, Cancer Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Cancer 97:121-7. 2003
    ....
  58. ncbi Microrna profiling analysis of differences between the melanoma of young adults and older adults
    Drazen M Jukic
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
    J Transl Med 8:27. 2010
    ....
  59. ncbi Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Immunol Res 50:235-47. 2011
    ....
  60. ncbi Natural killer-dendritic cell cross-talk in cancer immunotherapy
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15260, USA
    Expert Opin Biol Ther 5:1303-15. 2005
    ..Stage I/II clinical trials that are being implemented at present should allow evaluation of the immunological and clinical efficacy of combined NK-DC therapy of melanoma and other cancers...
  61. ncbi Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
    Julien Fourcade
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213, USA
    J Exp Med 207:2175-86. 2010
    ..Collectively, our findings support the use of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma...
  62. ncbi Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses
    Stergios J Moschos
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 24:3164-71. 2006
    ..CONCLUSION: Neoadjuvant HDI is highly effective for the treatment of palpable stage IIIB-C melanoma, and the findings of this study implicate an indirect immunomodulatory mechanism rather than a direct antitumor mechanism...
  63. ncbi Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article
    Donald N Liew
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Neurosurg 114:769-79. 2011
    ..To evaluate the role of stereotactic radiosurgery (SRS) in the management of brain metastases from melanoma, the authors assessed clinical outcomes and prognostic factors for survival and tumor control...
  64. ncbi Integrins and cancer
    Stergios J Moschos
    Department of Medicine, Division of Hematology Oncology, Melanoma and Skin Cancer Program, University of Pittsburgh, Cancer Institute, USA
    Oncology (Williston Park) 21:13-20. 2007
    ..Furthermore, it provides a synopsis on the clinical advancements in integrin targeting for therapeutic and imaging purposes in cancer...
  65. ncbi Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells
    Payal B Watchmaker
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Immunol 184:591-7. 2010
    ....
  66. ncbi A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6
    Lazar Vujanovic
    Department of Immunology, University of Pittsburgh School of Medicine, University Medical Center, Pittsburgh, PA 15213, USA
    Clin Cancer Res 13:6796-806. 2007
    ..The identification of tumor antigenic epitopes presented promiscuously by many HLA-DR alleles would extend the clinical utility of these peptides in vaccines and for the immunomonitoring of cancer patients...
  67. ncbi Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer 112:1131-8. 2008
    ..Arsenic trioxide (ATO) cytotoxicity and apoptosis induction has been demonstrated with numerous cancer cell lines, including human melanoma...
  68. ncbi New challenges in endpoints for drug development in advanced melanoma
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, CA90095, USA
    Clin Cancer Res 18:336-41. 2012
    ....
  69. ncbi Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b
    Zoya R Yurkovetsky
    University of Pittsburgh Cancer Institute, Pennsylvania 15213, USA
    Clin Cancer Res 13:2422-8. 2007
    ..Development of reliable serum assays may contribute to the development of methods for earlier detection of melanoma and the selection of patients who may be most susceptible to current available interventions with IFNalpha...
  70. ncbi Helper role of NK cells during the induction of anticancer responses by dendritic cells
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Mol Immunol 42:535-9. 2005
    ..We are currently implementing stage I/II clinical trials, testing the effectiveness of DC1s induced by NK cells or by NK cell-related factors, as therapeutic vaccines against melanoma...
  71. ncbi Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Onco
    Sanjiv S Agarwala
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Cancer 100:1692-8. 2004
    ....
  72. ncbi Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma
    Tomohide Tatsumi
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Exp Med 196:619-28. 2002
    ..Our data suggest that immunotherapeutic approaches will likely have to overcome or complement systemic Th2-dominated, tumor-reactive CD4(+) T cell responses to provide optimal clinical benefit...
  73. ncbi Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin
    Ahmad A Tarhini
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 17:6574-81. 2011
    ..We conducted a multicenter phase II study in patients with inoperable stage III or IV melanoma and no prior chemotherapy...
  74. ncbi Clinical and immunologic basis of interferon therapy in melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Ann N Y Acad Sci 1182:47-57. 2009
    ..Research of IFN-alpha in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response...
  75. ncbi Neoadjuvant therapy for high-risk bulky regional melanoma
    Ahmad A Tarhini
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Surg Oncol 104:386-90. 2011
    ..This will simplify the evaluation of promising new combinations of agents with HDI to build on the clinical, immunologic, and molecular effect of this therapy for patients with melanoma...
  76. ncbi A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 2584, USA
    Cancer 115:859-68. 2009
    ..Phase 1 studies demonstrated evidence of recombinant human IL-18 (rhIL-18)-mediated immunomodulatory and clinical activity, and defined a biologically active dose range...
  77. ncbi Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study
    Sanjiv S Agarwala
    Division of Hematology Oncology, University of Pittsburgh Medical Center Pavilion, 5150 Centre Ave, Pittsburgh, PA 15232, USA
    J Clin Oncol 22:2101-7. 2004
    ..A multicenter, open-label, phase II study was conducted to assess the safety and efficacy of temozolomide in patients with brain metastases from metastatic melanoma (MM) who did not require immediate radiotherapy...
  78. ncbi Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, PA 15213, USA
    Nat Clin Pract Oncol 2:240-1. 2005
  79. ncbi Long-term survivors after gamma knife radiosurgery for brain metastases
    Douglas Kondziolka
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, PA 15213, USA
    Cancer 104:2784-91. 2005
    ..The authors evaluated all brain metastasis in patients who lived for > or = 4 years after radiosurgery to determine clinical and treatment patterns potentially responsible for their outcome...
  80. ncbi Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features
    T Clark Gamblin
    Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Ann Surg Oncol 13:1664-70. 2006
    ..Sentinel lymph node biopsy (SLNB) is routinely used as a staging procedure for melanomas, however may also assist in understanding the biology of atypical and controversial spitzoid melanocytic skin lesions...
  81. ncbi Update on adjuvant interferon therapy for high-risk melanoma
    Sanjiv S Agarwala
    Melanoma Center, University of Pittsburgh Cancer Institute, USA
    Oncology (Williston Park) 16:1177-87; discussion 1190-2, 1197. 2002
    ..The use of surgical staging will help to better define prognostic groups and support ongoing efforts for more effective adjuvant therapy...
  82. ncbi Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients
    Douglas M Potter
    Biostatistics Facility, University of Pittsburgh Cancer Institute, 201 North Craig Street, Suite 325, Pittsburgh, PA 15213, United States
    J Immunol Methods 376:108-12. 2012
    ..We describe a new study of the association of serum biomarker level with overall survival in melanoma patients, and the problems encountered in carrying it out...
  83. ncbi Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 364:2507-16. 2011
    ..Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation...
  84. ncbi Management of metastatic melanoma
    Hussein A Tawbi
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Semin Oncol 34:532-45. 2007
    ..The rational use of agents capable of abrogating drug resistance offers other opportunities for systemic chemotherapy that may then give rise to more rationally developed combinations...
  85. ncbi Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pennsylvania, USA
    Cancer 95:1101-12. 2002
    ....
  86. ncbi Adjuvant therapy of melanoma
    Larisa Geskin
    Department of Dermatology, University of Pittsburgh, Melanoma Center UPCI, Pittsburgh, PA 15213, USA
    Semin Cutan Med Surg 22:55-67. 2003
  87. ncbi Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes
    Shannon L McDonald
    Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Cancer Biol Ther 3:110-20. 2004
    ..7 kD Hypothetical Protein) in benign and atypical nevocytic lesions, advanced-stage melanomas, and melanoma-positive lymph nodes...
  88. ncbi Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Melanoma and Skin Cancer Program, Department of Medicine, UPMC Cancer Pavilion, 5150 Centre Avenue, Room 559, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 8:1583-93. 2008
    ..Additional Phase II and III studies in combination with other agents will assess antitumor activity in multiple tumor types as well as attempt to identify patient populations most likely to respond...
  89. ncbi Radiosurgery for the treatment of spinal melanoma metastases
    Peter C Gerszten
    Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Stereotact Funct Neurosurg 83:213-21. 2005
    ..This study evaluated the clinical efficacy of radiosurgery for the treatment of melanoma spinal metastases in 28 patients...
  90. ncbi Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression
    Laura Strauss
    University of Pittsburgh Cancer Institute, Department of Medicine, School of Medicine, Pittsburgh, PA 15232, USA
    J Immunol 180:2967-80. 2008
    ..As CD4+CD25highFoxp3+ naturally occurring T regulatory cells in melanoma patients express ICOS, we investigated the impact of ICOS on naturally occurring T regulatory cell function...
  91. ncbi Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics
    Talal El-Hefnawy
    Division of Thoracic Surgery, School of Medicine, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Clin Chem 50:564-73. 2004
    ..Despite optimizing many aspects of plasma RNA detection, we were unable to reproducibly detect cancer-related transcripts. Our data suggest that measurement of circulating RNA may not be a good approach to early cancer diagnosis...
  92. ncbi Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, 5150 Centre Avenue, 5th Floor Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 9:505-14. 2007
    ..Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer...
  93. ncbi alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity
    Robbie B Mailliard
    Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213-1863, USA
    Cancer Res 64:5934-7. 2004
    ..Serum-free generation of alphaDC1 allows, for the first time, the clinical application of DCs that combine the key three features important for their efficacy as anticancer vaccines...
  94. ncbi Melanoma vaccines: early progress and future promises
    Hassane M Zarour
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Semin Cutan Med Surg 22:68-75. 2003
    ....
  95. ncbi NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells
    Hassane M Zarour
    Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Cancer Res 62:213-8. 2002
    ..They support the relevance of cancer vaccine trials with the NY-ESO-1 119-143 peptide in the large number of cancer patients with NY-ESO-1-expressing tumors...
  96. ncbi Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver
    Sanjiv S Agarwala
    University of Pittsburgh Cancer Institute, 5th Floor, 5150 Centre Ave, Pittsburgh, PA 15232, USA
    Melanoma Res 14:217-22. 2004
    ..The overall response rate was 16%. Dose-limiting toxicities included renal, hepatic and haematological effects. This therapy produces a modest response rate in patients with ocular melanoma and liver metastases...
  97. ncbi Oblimersen in the treatment of metastatic melanoma
    Ahmad A Tarhini
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, UPCI UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Future Oncol 3:263-71. 2007
    ..This article reviews the biochemistry, pharmacodynamics and pharmacokinetics, safety and efficacy data related to oblimersen in melanoma...
  98. ncbi Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
    Sanjiv S Agarwala
    Melanoma Center, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 20:125-33. 2002
    ..This study was designed to determine whether the addition of histamine to a subcutaneous (SC) regimen of interleukin-2 (IL-2) would improve the survival of metastatic melanoma patients...
  99. ncbi Highlights from the perspectives in melanoma XII conference
    John M Kirkwood
    Medicine and Dermatology, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Pigment Cell Melanoma Res 22:156-65. 2009
    ..Selected reviews are included but further discussions of these and other presentations are posted at http://www.MelanomaCare.org...
  100. ncbi Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
    John M Kirkwood
    University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:3703-18. 2002
    ..It is important to understand the expected adverse events and their underlying mechanisms and to anticipate and aggressively manage toxicity during treatment in order to ensure that patients receive the maximum therapeutic benefit...
  101. ncbi Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited
    Kelly M McMasters
    Arch Dermatol 139:99; author reply 99-100. 2003